<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37390009</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1465-2099</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of general virology</Title><ISOAbbreviation>J Gen Virol</ISOAbbreviation></Journal><ArticleTitle>Production of antigenically stable enterovirus A71 virus-like particles in <i>Pichia pastoris</i> as a vaccine candidate.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">001867</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1099/jgv.0.001867</ELocationID><Abstract><AbstractText>Enterovirus A71 (EVA71) causes widespread disease in young children with occasional fatal consequences. In common with other picornaviruses, both empty capsids (ECs) and infectious virions are produced during the viral lifecycle. While initially antigenically indistinguishable from virions, ECs readily convert to an expanded conformation at moderate temperatures. In the closely related poliovirus, these conformational changes result in loss of antigenic sites required to elicit protective immune responses. Whether this is true for EVA71 remains to be determined and is the subject of this investigation.We previously reported the selection of a thermally resistant EVA71 genogroup B2 population using successive rounds of heating and passage. The mutations found in the structural protein-coding region of the selected population conferred increased thermal stability to both virions and naturally produced ECs. Here, we introduced these mutations into a recombinant expression system to produce stabilized virus-like particles (VLPs) in <i>Pichia pastoris</i>.The stabilized VLPs retain the native virion-like antigenic conformation as determined by reactivity with a specific antibody. Structural studies suggest multiple potential mechanisms of antigenic stabilization, however, unlike poliovirus, both native and expanded EVA71 particles elicited antibodies able to directly neutralize virus <i>in vitro</i>. Therefore, anti-EVA71 neutralizing antibodies are elicited by sites which are not canonically associated with the native conformation, but whether antigenic sites specific to the native conformation provide additional protective responses <i>in vivo</i> remains unclear. VLPs are likely to provide cheaper and safer alternatives for vaccine production and these data show that VLP vaccines are comparable with inactivated virus vaccines at inducing neutralising antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kingston</LastName><ForeName>Natalie J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snowden</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martyna</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shegdar</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grehan</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedcastle</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegg</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macadam</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogle</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlands</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonehouse</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular &amp; Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P022626/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI169457</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Gen Virol</MedlineTA><NlmUniqueID>0077340</NlmUniqueID><ISSNLinking>0022-1317</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000676904">Komagataella pastoris</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2023 Feb 02:2023.01.30.526315. doi: 10.1101/2023.01.30.526315</RefSource><PMID Version="1">36778240</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EVA71</Keyword><Keyword MajorTopicYN="N">VLP</Keyword><Keyword MajorTopicYN="N">hand, foot and mouth disease, virus-like particle</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37390009</ArticleId><ArticleId IdType="pmc">PMC10773253</ArticleId><ArticleId IdType="doi">10.1099/jgv.0.001867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of Enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13:e1001958. doi: 10.1371/journal.pmed.1001958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001958</ArticleId><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization, W.H  Enterovirus 71. 2022. Apr 4, https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/enterovirus-71</Citation></Reference><Reference><Citation>Li M-L, Shih S-R, Tolbert BS, Brewer G. Enterovirus A71 Vaccines. Vaccines. 2021;9:199. doi: 10.3390/vaccines9030199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030199</ArticleId><ArticleId IdType="pmc">PMC7997495</ArticleId><ArticleId IdType="pubmed">33673595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Langmuir AD. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol. 1995;142:109–140. doi: 10.1093/oxfordjournals.aje.a117611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a117611</ArticleId><ArticleId IdType="pubmed">7598112</ArticleId></ArticleIdList></Reference><Reference><Citation>Offit PA. The Cutter incident, 50 years later. N Engl J Med. 2005;352:1411–1412. doi: 10.1056/NEJMp048180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp048180</ArticleId><ArticleId IdType="pubmed">15814877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bull World Health Organ. 2004;82:59–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585887</ArticleId><ArticleId IdType="pubmed">15106302</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulders MN, Reimerink JH, Koopmans MP, van Loon AM, van der Avoort HG. Genetic analysis of wild-type poliovirus importation into The Netherlands (1979-1995) J Infect Dis. 1997;176:617–624. doi: 10.1086/514081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/514081</ArticleId><ArticleId IdType="pubmed">9291306</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 &amp; 2003. Indian J Med Res. 2003;118:217–223.</Citation><ArticleIdList><ArticleId IdType="pubmed">14870793</ArticleId></ArticleIdList></Reference><Reference><Citation>Duizer E, Rutjes S, de Roda Husman AM, Schijven J. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. Euro Surveill. 2016;21:30169. doi: 10.2807/1560-7917.ES.2016.21.11.30169.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.11.30169</ArticleId><ArticleId IdType="pubmed">27020766</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Wang Y, Tao L, Wu X, Wu W. Recombinant Lactococcus lactis secreting viral protein 1 of enterovirus 71 and its immunogenicity in mice. Biotechnol Lett. 2019;41:867–872. doi: 10.1007/s10529-019-02695-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-019-02695-1</ArticleId><ArticleId IdType="pubmed">31119429</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Chow VTK, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299–1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Phoon MC, Ramachandran NP, Chow VTK, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61–68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Chou A-H, Lien S-P, Lin H-Y, Liu S-J, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362–4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444–7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855–1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335–2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H-Y, Han J-F, Qin C-F, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281–3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Kumar P. Yeast-based vaccines: new perspective in vaccine development and application. FEMS Yeast Res. 2019;19:foz007. doi: 10.1093/femsyr/foz007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsyr/foz007</ArticleId><ArticleId IdType="pubmed">30668686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424–429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 a resolution. Protein Sci. 1994;3:1651–1669. doi: 10.1002/pro.5560031005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031005</ArticleId><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Wang X, Zhu L, Hu Z, Gao Q, et al. Structures of Coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol. 2015;89:10500–10511. doi: 10.1128/JVI.01102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01102-15</ArticleId><ArticleId IdType="pmc">PMC4580203</ArticleId><ArticleId IdType="pubmed">26269176</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyemi OO, Nicol C, Stonehouse NJ, Rowlands DJ. Increasing type 1 Poliovirus capsid stability by thermal selection. J Virol. 2017;91:e01586-16. doi: 10.1128/JVI.01586-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01586-16</ArticleId><ArticleId IdType="pmc">PMC5286869</ArticleId><ArticleId IdType="pubmed">27928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically thermo-stabilised, immunogenic Poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog. 2017;13:e1006117. doi: 10.1371/journal.ppat.1006117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006117</ArticleId><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsian J, Fox H, Bahar MW, Kotecha A, Fry EE, et al. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat Commun. 2017;8:245. doi: 10.1038/s41467-017-00090-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00090-w</ArticleId><ArticleId IdType="pmc">PMC5557999</ArticleId><ArticleId IdType="pubmed">28811473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston NJ, Shegdar M, Snowden JS, Fox H, Groppelli E, et al. Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids. J Gen Virol. 2022;103:001771. doi: 10.1099/jgv.0.001771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001771</ArticleId><ArticleId IdType="pmc">PMC10019091</ArticleId><ArticleId IdType="pubmed">35997623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Grehan K, Snowden JS, Knight ML, Adeyemi OO, et al. Comparative molecular biology approaches for the production of Poliovirus virus-like particles using Pichia pastoris . mSphere. 2020;5:e00838-19. doi: 10.1128/mSphere.00838-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00838-19</ArticleId><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston NJ, Grehan K, Snowden JS, Shegdar M, Fox H, et al. Development of an enzyme-linked immunosorbent assay for detection of the native conformation of enterovirus A71. mSphere. 2022;7:e0008822. doi: 10.1128/msphere.00088-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00088-22</ArticleId><ArticleId IdType="pmc">PMC9241546</ArticleId><ArticleId IdType="pubmed">35642505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedcastle A. WHO/BS/2019.2362 WHO 1st IS for Enterovirus A71 inactivated vaccine. 2019.</Citation></Reference><Reference><Citation>Scheres SHW. RELION: implementation of a bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180:519–530. doi: 10.1016/j.jsb.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2012.09.006</ArticleId><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife. 2018;7:e42166. doi: 10.7554/eLife.42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.42166</ArticleId><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache J-P, Verba KA, Cheng Y, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4193</ArticleId><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216–221. doi: 10.1016/j.jsb.2015.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.08.008</ArticleId><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T, Merino F, Stabrin M, Moriya T, Antoni C, et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun Biol. 2019;2:218. doi: 10.1038/s42003-019-0437-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0437-z</ArticleId><ArticleId IdType="pmc">PMC6584505</ArticleId><ArticleId IdType="pubmed">31240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW, Chen S. Prevention of overfitting in cryo-EM structure determination. Nat Methods. 2012;9:853–854. doi: 10.1038/nmeth.2115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2115</ArticleId><ArticleId IdType="pmc">PMC4912033</ArticleId><ArticleId IdType="pubmed">22842542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–221. doi: 10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21. doi: 10.1107/S0907444909042073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27:14–25. doi: 10.1002/pro.3235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3235</ArticleId><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DJ, Heath AB. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals. 1995;23:301–311. doi: 10.1006/biol.1995.0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/biol.1995.0049</ArticleId><ArticleId IdType="pubmed">8825859</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>